ABVC Abvc Biopharma (ABVC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001173313
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter
Abvc Biopharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for ABVC BIOPHARMA, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 82% of Pharma & Biotech
Revenue
+0.0% year over year
below 56% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.3% of the float short (float per yahoo 2026-10-26) · 3.6 days to cover · settled 2026-09-30
below 67% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ABVC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns ABVC: institutional holders (13F)
13F holdings, latest reported quarter
374,499 sh
$591.7K
228,042 sh
$360.4K
97,363 sh
$153.8K
72,800 sh
$115.0K
72,091 sh
$113.9K
Congress trades in ABVC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ABVC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ABVC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$154.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$329.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$40.4K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$43.8K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$8.6K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$182.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ABVC financials
Revenue growth
0.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM ABVC
| FY Dec 2025 | n/a |
| FY Dec 2024 | $509.6K |
| FY Dec 2023 | $152.4K |
| FY Dec 2022 | $969.8K |
| FY Dec 2021 | $355.8K |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$499.9K |
| Sep 2025 | $796.0K |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $2.0K |
| Sep 2024 | $389.3K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM ABVC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -256.6% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -101.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM ABVC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$7.5M |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.02x
long-term 2020-09-30 (69 months older than the period end) plus current 2026-06-30; equity 2026-06-30
Debt to equity ABVC
| FY Dec 2025 | 0.08x |
| FY Dec 2024 | 0.79x |
| FY Dec 2023 | 0.66x |
| FY Dec 2022 | 0.65x |
| FY Dec 2021 | 0.20x |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.02x |
| Dec 2025 | 0.08x |
| Sep 2025 | 0.08x |
| Jun 2025 | 0.14x |
| Mar 2025 | 0.17x |
| Dec 2024 | 0.79x |
| Sep 2024 | 0.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-14.64x
TTM operating cash flow over long-term 2020-09-30 (69 months older than the period end) plus current 2026-06-30
Cash flow to debt ABVC
| FY Dec 2025 | -3.39x |
| FY Dec 2024 | -1.88x |
| FY Dec 2023 | -4.09x |
| FY Dec 2022 | -3.67x |
| FY Dec 2021 | -4.31x |
| Jun 2026 | -14.64x |
| Mar 2026 | -15.67x |
| Dec 2025 | -3.39x |
| Sep 2025 | -3.32x |
| Jun 2025 | -2.08x |
| Mar 2025 | -1.50x |
| Dec 2024 | -1.88x |
| Sep 2024 | -1.51x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-82.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ABVC
| FY Dec 2025 | -128.2% |
| FY Dec 2024 | -352.7% |
| FY Dec 2023 | -334.8% |
| FY Dec 2022 | -275.0% |
| FY Dec 2021 | n/a |
| Jun 2026 | -82.2% |
| Mar 2026 | -106.7% |
| Dec 2025 | -128.2% |
| Sep 2025 | -85.7% |
| Jun 2025 | -96.0% |
| Mar 2025 | -81.9% |
| Dec 2024 | -352.7% |
| Sep 2024 | -84.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-39.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ABVC
| FY Dec 2025 | -55.3% |
| FY Dec 2024 | -64.0% |
| FY Dec 2023 | -89.7% |
| FY Dec 2022 | -141.1% |
| FY Dec 2021 | n/a |
| Jun 2026 | -39.9% |
| Mar 2026 | -49.9% |
| Dec 2025 | -55.3% |
| Sep 2025 | -40.5% |
| Jun 2025 | -34.8% |
| Mar 2025 | -25.5% |
| Dec 2024 | -64.0% |
| Sep 2024 | -37.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital ABVC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-55.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ABVC
| FY Dec 2025 | -90.1% |
| FY Dec 2024 | -353.1% |
| FY Dec 2023 | -236.7% |
| FY Dec 2022 | -215.3% |
| FY Dec 2021 | -139.6% |
| Jun 2026 | -55.7% |
| Mar 2026 | -71.4% |
| Dec 2025 | -90.1% |
| Sep 2025 | -69.8% |
| Jun 2025 | -69.4% |
| Mar 2025 | -51.5% |
| Dec 2024 | -353.1% |
| Sep 2024 | -70.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
no close on file at or before the as-of date
P/E, trailing ABVC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no close on file at or before the as-of date
Enterprise value ABVC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no close on file at or before the as-of date
FCF yield ABVC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
no close on file at or before the as-of date
PEG, trailing ABVC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $296.0K | $509.6K | $152.4K | $969.8K |
| Gross profit | n/a | $508.8K | -$149.6K | $683.4K |
| Operating income | -$7.2M | -$4.7M | -$6.8M | -$15.1M |
| Net income | -$7.9M | -$4.9M | -$7.8M | -$16.4M |
| EPS (diluted) | -0.39 | -0.42 | -1.80 | -5.19 |
| Operating cash flow | -$3.0M | -$1.8M | -$4.2M | -$7.4M |
| Cash | $681.5K | $248.4K | $60.2K | $85.3K |
SEC XBRL, fiscal years, as known on 2026-10-27
ABVC Stock Sonar score 5/7 axes
Find similar shapesCompareABVC ranks highest on risk and compliance (82nd percentile) and financial health (47th), and lowest on institutional and government (18th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
